The χ<sup>2</sup> and Fisher's exact tests showed that VEGFR1 expression was related to lymph node metastasis (<i>P</i> = 0.013), while no relationships between TUBB3 and clinicopathological features were observed.
The expression of TUBB3 gene was obviously higher in NSCLC patients in phases I/II and IV than those in phase III (P1=0.021; P2=0.004), and it was also markedly higher in patients without lymph node metastasis than those with (P=0.008).
Overexpression of TUBB3 protein was observed in 56 (85%) of the 66 ovarian cancers, and was significantly associated with aggressive tumor behavior (advanced stage, presence of ascites, suboptimal cytoreduction at surgery and presence of lymph node metastasis) (P<0.05).